A Long-term Follow-up Study of Patients Who Received VOR33
Palo Alto (17 mi)Age: Any Age
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: N/A
Recruiting
Sponsor: Vor Biopharma
No Placebo Group
Approved in 1 jurisdiction
Trial Summary
What is the purpose of this trial?VOR33 long-term follow-up (LTFU) study
Eligibility Criteria
Inclusion Criteria
1. Has received any part of or all of a VOR33 infusion
Treatment Details
1Treatment groups
Experimental Treatment
Group I: Observational Cohort 1Experimental Treatment1 Intervention
All patients who have received any part of or all of a VOR33 genome-edited hematopoietic stem and progenitor cell therapy product.
VOR33 is already approved in United States for the following indications:
🇺🇸 Approved in United States as trem-cel for:
- Acute Myeloid Leukemia (AML)
Find a clinic near you
Research locations nearbySelect from list below to view details:
National Institutes of Health, Clinical CenterBethesda, MD
University of California San Diego Moores Cancer CenterLa Jolla, CA
Miami Cancer InstituteMiami, FL
John Theurer Cancer Center at Hackensack University Medical CenterHackensack, NJ
More Trial Locations
Loading ...
Who is running the clinical trial?
Vor BiopharmaLead Sponsor